Acceleron Pharma

Belkins
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases.

Related News

DURHAM’S MYCOVIA PHARMA EXTENDS CLINICAL TRIAL OF ANTI-FUNGAL DRUG FOR YEAST INFECTIONS

WRAL TechWire | February 11, 2020

news image

Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwi...

Read More

PHARMACY MARKET

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Novartis | December 17, 2020

news image

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More

RESEARCH

ETHYPHARM TO ACQUIRE ALTAN PHARMA, ALLOWING IT TO ENTER THE SPANISH MARKET AND EXPAND ITS CRITICAL CARE PORTFOLIO AND R&D PIPELINE.

Ethypharm | June 19, 2021

news image

Ethypharm reports today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use. On account of the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the main 5 European markets after shutting, which is expected in the second half of 2021. Ethypharm will likewise profit with an enlarged portfolio of great hospital...

Read More

PHARMACY MARKET

PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE

Pfizer | August 17, 2021

news image

Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...

Read More

WRAL TechWire | February 11, 2020

news image

DURHAM’S MYCOVIA PHARMA EXTENDS CLINICAL TRIAL OF ANTI-FUNGAL DRUG FOR YEAST INFECTIONS

Mycovia Pharmaceuticals, a developer of drugs in women’s health, has initiated “extension studies” as part of its ongoing Phase 3 global clinical trial of its lead drug candidate for treating recurrent yeast infections in women. The Durham-based firm is developing oteseconazole (VT-1161), an oral antifungal product candidate, for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwi...

Read More

PHARMACY MARKET

Novartis | December 17, 2020

news image

NOVARTIS' SANDOZ SPOTLIGHTS IMPORTANCE OF GENERIC DRUGS IN NEW SOCIAL CAMPAIGN

Did you realize that 90% of remedies are composed for nonexclusive medications? Novartis' Sandoz is getting the news out about nonexclusive medication with such realities in its as of late dispatched "Request Generics" crusade. It's Sandoz's first significant instruction and mindfulness crusade via online media to advance the estimation of generics. The intended interest group is key partners—patients, clinicians, policymakers and payers—with mess...

Read More

RESEARCH

Ethypharm | June 19, 2021

news image

ETHYPHARM TO ACQUIRE ALTAN PHARMA, ALLOWING IT TO ENTER THE SPANISH MARKET AND EXPAND ITS CRITICAL CARE PORTFOLIO AND R&D PIPELINE.

Ethypharm reports today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use. On account of the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the main 5 European markets after shutting, which is expected in the second half of 2021. Ethypharm will likewise profit with an enlarged portfolio of great hospital...

Read More

PHARMACY MARKET

Pfizer | August 17, 2021

news image

PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE

Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...

Read More